Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1972 1
1973 1
1975 1
1976 1
1977 5
1978 3
1979 2
1980 7
1981 3
1982 5
1983 3
1984 5
1985 3
1986 3
1987 4
1988 8
1989 4
1990 5
1991 13
1992 5
1993 7
1994 10
1995 14
1996 4
1997 4
1998 3
1999 1
2000 2
2001 4
2003 1
2004 6
2005 6
2006 7
2007 7
2008 6
2009 8
2010 8
2011 4
2012 8
2013 4
2014 2
2015 4
2016 6
2017 12
2018 9
2019 9
2020 8
2021 6
2022 6
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

261 results

Results by year

Filters applied: . Clear all
Page 1
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion.
Campuzano V, Montermini L, Moltò MD, Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Cañizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, Pandolfo M. Campuzano V, et al. Among authors: di donato s. Science. 1996 Mar 8;271(5254):1423-7. doi: 10.1126/science.271.5254.1423. Science. 1996. PMID: 8596916
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. Cremolini C, et al. Among authors: di donato s. Lancet Oncol. 2020 Apr;21(4):497-507. doi: 10.1016/S1470-2045(19)30862-9. Epub 2020 Mar 9. Lancet Oncol. 2020. PMID: 32164906 Free article. Clinical Trial.
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Pella N, Bergamo F, Raimondi A, Arnoldi E, Antonuzzo L, Granetto C, Zustovich F, Ronzoni M, Leo S, Morano F, Loupakis F, Buggin F, Zagonel V, Fassan M, Cremolini C, Boni L, Pietrantonio F; GONO Foundation Investigators. Lonardi S, et al. Among authors: di donato s. J Clin Oncol. 2023 Dec 1;41(34):5263-5273. doi: 10.1200/JCO.23.00506. Epub 2023 Aug 3. J Clin Oncol. 2023. PMID: 37535876 Clinical Trial.
Cellular and Molecular Diversity in Scleroderma.
Hinchcliff M, Garcia-Milian R, Di Donato S, Dill K, Bundschuh E, Galdo FD. Hinchcliff M, et al. Among authors: di donato s. Semin Immunol. 2021 Dec;58:101648. doi: 10.1016/j.smim.2022.101648. Epub 2022 Aug 6. Semin Immunol. 2021. PMID: 35940960 Review.
Cerebellar/spinocerebellar syndromes.
Mariotti C, Di Donato S. Mariotti C, et al. Among authors: di donato s. Neurol Sci. 2001 Nov;22 Suppl 2:S88-92. doi: 10.1007/s100720100042. Neurol Sci. 2001. PMID: 11794486 Review.
Mitochondrial disorders.
Zeviani M, Di Donato S. Zeviani M, et al. Among authors: di donato s. Brain. 2004 Oct;127(Pt 10):2153-72. doi: 10.1093/brain/awh259. Epub 2004 Sep 9. Brain. 2004. PMID: 15358637 Review.
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Pietrantonio F, Bergamo F, Rossini D, Ghelardi F, De Grandis MC, Germani MM, Barsotti G, Formica V, Frassineti GL, Boscolo G, Cinieri S, Di Donato S, Antonuzzo L, Antoniotti C, Ambrosini M, Piva VM, Nichetti F, Fassan M, Cremolini C, Lonardi S. Pietrantonio F, et al. Among authors: di donato s. Eur J Cancer. 2023 Dec;195:113396. doi: 10.1016/j.ejca.2023.113396. Epub 2023 Oct 20. Eur J Cancer. 2023. PMID: 37924647 Free article.
Emerging treatments in myopathies.
Antozzi C, Confalonieri P, Mantegazza R, Di Donato S. Antozzi C, et al. Among authors: di donato s. Eur Neurol. 1997;38(3):222-9. doi: 10.1159/000113377. Eur Neurol. 1997. PMID: 9363835 Review.
An overview of the patient with ataxia.
Mariotti C, Fancellu R, Di Donato S. Mariotti C, et al. Among authors: di donato s. J Neurol. 2005 May;252(5):511-8. doi: 10.1007/s00415-005-0814-z. J Neurol. 2005. PMID: 15895274 Review.
261 results